13. “Selective a7 nicotinic receptor agonists and positive allosteric modulators for the treatment of schizophrenia – a review”, Antonio-Tolentino, K.; Hopkins, C. R.*Expert Opin. Investig. Drugs.2020, DOI: 10.1080/13543784.2020.1764938.
12. “A review of TRPC modulators and disease”, Sharma, S.; Hopkins, C. R.*J. Med. Chem. 2019, Perspective Accepted. ASAP April 3, 2019. DOI: 10.1021/acs.jmedchem.8b01954.
11. "Discovery of small molecule ROMK inhibitors: A brief history of medicinal chemistry approaches to develop novel diuretic therapeutics", Aretz, C. D.; Vadukoot, A. K.; Hopkins, C. R.*J. Med. Chem. 2019, 62, 8682-8694. DOI: 10.1021/acs.jmedchem.8b01891
10. “The return of the D4 dopamine receptor in drug discovery”, Lindsley, C. W.; Hopkins, C. R.*J. Med. Chem.2017, 60, 7233-7243. DOI: 10.1021/acs.jmedchem.7b00151.
9. “Inhibitors of the bone morphogenetic protein (BMP) signaling pathway: a patent review (2008-2015)”, Hopkins, C. R.*Expert Opin. Ther. Patents2016, 10, 1115-1128. DOI: 10.1080/13543776.2016.1217330.
8. “Practical strategies and concepts in GPCR allosteric modulator discovery: recent advances with metabotropic glutamate receptors”, Emmitte, K. A.; Hopkins, C. R.; Bridges, T. M.; Gregory, K. J.; Niswender, C. M.; Conn, P. J.*; Lindsley, C. W.* Chem. Rev.2016, 116, 6707-6741. DOI: 10.1021/acs.chemrev.5b00656.
7. “Metabotropic glutamate receptor 4 (mGlu4) positive allosteric modulators for the treatment of Parkinson’s disease: Historical perspective and review of the patent literature”, Lindsley, C. W.; Hopkins, C. R.*Expert Opin. Ther. Patents2012, 461-481. DOI: 10.1517/13543776.2012.679437. PMID: 22506633.
6. “Allosteric Modulation of 7 Transmembrane Spanning Receptors: Theory, Practice and Opportunities for CNS Drug Discovery”, Melancon, B. J.; Hopkins, C. R.; Wood, M. R.; Emmitte, K. A.; Niswender, C. M.; Christopolous, A.; Conn, P. J.; Lindsley, C. W.* J. Med. Chem. (Perspective)2012, 55, 1445-1464. DOI: 10.1021/jm201139r. PMID: 22148748.
Top Ten Most Most Read Article of 2012.
5. “Recent Progress on the Identification of Metabotropic Glutamate 4 Receptor Ligands and Their Potential Utility as CNS Therapeutics”, Robichaud, A. J.*; Engers, D. W.; Lindsley, C. W.; Hopkins, C. R.*ACS Chem. Neurosci.2011, 2, 433-449. DOI: 10.1021/cn200043e. PMID: 22860170.
4. “Molecular Switches” on mGluR Allosteric Ligands that Modulate Modes of Pharmacology”, Wood, M. R.; Hopkins, C. R.; Brogan, J. T.; Conn, P. J.; Lindsley, C. W.* Biochemistry2010, 50, 2403-2410. DOI: 10.1021/bi200129s. PMID: 21341760.
3. “The antipsychotic potential of muscarinic allosteric modulation”, Bridges, T. M.; LeBois, E. P.; Hopkins, C. R.; Wood, M. R.; Jones, C. K.; Conn, J. P.; Lindsley, C. W.* Drug News Perspect.2010, 23, 229-240. DOI: 10.1358/dnp.2010.23.4.1416977. PMID: 20520852.
2. “Recent Progress in the Development of mGluR4 Positive Allosteric Modulators for the Treatment of Parkinson’s Disease”, Lindsley, C. W.; Engers, D. W.; Niswender, C. M.; Hopkins, C. R.* Curr. Top. Med. Chem.2009, 9, 949-963. PMID: 19754407.
1. “mGluR4-positive allosteric modulation as potential treatment for Parkinson’s disease”, Hopkins, C. R.*; Lindsley, C. W.; Niswender, C. M. Future Med. Chem.2009, 1, 501-513. DOI: 10.4155/fmc.09.38. PMID: 20161443.
Book Chapters
2.. Melancon, B. J.; Hopkins, C. R.* ‘Muscarinic receptors allosteric modulation’ in Allosterism in Drug Discovery, Doller, D. Ed. Royal Society of Chemistry, 2016. (Invited)
1. Lindsley, C. W.; Hopkins, C. R.; Sulikowski, G. A. ‘Biomimetic Synthesis of Lignans’ in Biomimetic Organic Synthesis, Poupon, E.; Nay, B., Eds. Wiley-VCH Verlag GmbH & Co. KGaA, 2011, pp 677-693. (Invited)